- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
Drug guidance
Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
Condition
Kidney
Endocrine and metabolic
4 June 2025
-
Published on 04 Jun 2025
Last Updated on 04 Jun 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended finerenone for inclusion on the MOH List of Subsidised Drugs as an add-on to standard of care for treating adults with chronic kidney disease and albuminuria associated with type 2 diabetes. This decision was based on finerenone being unlikely to represent an acceptable use of healthcare resources at the price proposed by the company.